Investors & Media


DevaCell is a preclinical-stage biopharmaceutical company focused on developing next-generation synthetic vector-based immunotherapies based on the ONCoatTM synthetic vector platform technology. We are advancing a pipeline of product candidates that can be systemically delivery, with repeat administration possible, targeting a wide range of indications with significant unmet medical need. Our lead therapeutic program, DEVA-OV1, is a synthetic vector-based oncolytic virus therapy that is designed to selectively target and kill tumor cells, while also delivering immunomodulatory transgenes that synergistically activate and enhance the innate and adaptive immune system.

Our personal and profession mission and commitment is to positively impact patient care, which inspires and motivates each and every one of us every single day to do more and do more faster, in order to move down the path to improved patient care.

Leave a Reply

Your email address will not be published. Required fields are marked *